Gepotidacin

95 interactions 6 explained in plain English

Also sold as: Blujepa

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Nafcillin Injection Famotidine Injection Dihydroergotamine Injection Disopyramide Oxaliplatin Injection

1 Contraindicated 92 Major 2 Moderate

All (95) Contraindicated (1) Major (92) Moderate (2)

Major

Gepotidacin Encorafenib Braftovi Reduced gepotidacin efficacy and an increased risk of QT interval prolongation Details Gepotidacin Entrectinib Rozlytrek Increased CYP3A4 substrate with NTI exposure and an increased risk of QT interval prolongation Details Gepotidacin Eribulin Injection Halaven An increased risk of QT interval prolongation Details Gepotidacin Everolimus Afinitor Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Famotidine Calmicid An increased risk of QT interval prolongation Details Gepotidacin Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Gepotidacin Felbamate Felbatol An increased risk of QT interval prolongation Details Gepotidacin Fentanyl Transdermal Patch Duragesic® Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Gepotidacin Flecainide Tambocor® An increased risk of QT interval prolongation Details Gepotidacin Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Gepotidacin Galantamine Razadyne An increased risk of QT interval prolongation Details Gepotidacin Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Gepotidacin Gemifloxacin Factive An increased risk of QT interval prolongation Details Gepotidacin Glasdegib Daurismo An increased risk of QT interval prolongation Details Gepotidacin Goserelin Implant Zoladex An increased risk of QT interval prolongation Details Gepotidacin Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Gepotidacin Granisetron Injection Granisol An increased risk of QT interval prolongation Details Gepotidacin Histrelin Implant Supprelin An increased risk of QT interval prolongation Details Gepotidacin Hydroxychloroquine Plaquenil An increased risk of QT interval prolongation Details Gepotidacin Inotuzumab Ozogamicin Injection Besponsa An increased risk of QT interval prolongation Details Gepotidacin Ivabradine Corlanor An increased risk of QT interval prolongation Details Gepotidacin Lefamulin Xenleta Increased gepotidacin exposure and an increased risk of QT interval prolongation Details Gepotidacin Lenacapavir Injection Sunlenca Increased gepotidacin exposure Details Gepotidacin Lenacapavir Oral Sunlenca Increased gepotidacin exposure Details Gepotidacin Lenvatinib Lenvima An increased risk of QT interval prolongation Details Gepotidacin Letermovir Injection Prevymis Increased gepotidacin exposure Details Gepotidacin Levofloxacin Levaquin An increased risk of QT interval prolongation Details Gepotidacin Levofloxacin Injection Levaquin An increased risk of QT interval prolongation Details Gepotidacin Loperamide Diamode Increased loperamide exposure, an increased risk of loperamide-related adverse reactions and an increased risk of QT interval prol... Details Gepotidacin Mefloquine Lariam® An increased risk of QT interval prolongation Details Gepotidacin Methylergonovine Methergine Increased methylergonovine exposure Details Gepotidacin Metronidazole Flagyl An increased risk of QT interval prolongation Details Gepotidacin Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Gepotidacin Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Gepotidacin Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Gepotidacin Midostaurin Rydapt Increased CYP3A4 substrate with NTI exposure Details Gepotidacin Mitapivat Aqvesme Reduced gepotidacin exposure Details Gepotidacin Moxifloxacin Avelox An increased risk of QT interval prolongation Details Gepotidacin Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.